Increasing Access to Lung Cancer Screening Act

On May 19, 2026, Senator Durbin introduced S4566, the Increasing Access to Lung Cancer Screening Act. The bill would amend the Social Security Act to require state Medicaid plans to cover annual lung cancer screening for eligible individuals without cost sharing, and expand coverage of tobacco cessation counseling and pharmacotherapy. The bill was read twice and referred to the Committee on Finance. It is in early legislative stages with only one cosponsor and no companion bill in the House. No explicit funding authorization or appropriation is included. The Congressional Budget Office (CBO) would need to score the mandate for future appropriations. Since the bill imposes a coverage requirement on states, not a direct procurement or reimbursement program for private companies, there are no material revenue impacts for publicly traded firms. Diagnostic imaging equipment manufacturers (e.g., $GEHC, $SIEGY) and pharmaceutical cessation products ($JNJ, $PFIZER) could see theoretical volume increases, but the mandate does not create a new revenue stream—only shifts payer dynamics for an existing patient population. The legislative path requires full committee markup, full Senate vote, House introduction and passage, and presidential signature. Given the early stage, single sponsor, and lack of House companion, the probability of enactment in 2026 is low. No real market data exists to tie price movements to this bill. For retail investors, no actionable trade signal is present.